LIPT2

Across TCGA pan-cancer cohorts, LIPT2 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated LIPT2 data layer compared with 27 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LIPT2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated LIPT2 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

LSCC, LUAD, and CCRCC are the cancer types where LIPT2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Tertile	II,III,IV	1.000	0.593	.004	39	view →
LUAD	DFS	Quartile	II,III,IV	0.237	0.575	.014	18	view →
CCRCC	OS	Median	All	0.747	0.943	.011	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

LIPT2–LSCC (OS)

Open the LSCC breakdown →